OCUGEN, INC. Operating Lease, Weighted Average Discount Rate, Percent
OCUGEN, INC. (OCGN) had Operating Lease, Weighted Average Discount Rate, Percent of 10.30% as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-04
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.30%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 9.40%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 9.30%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 6.40%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2025-12-31 | 10.30% 10-K · filed 2026-03-04 | |
| 2024-12-31 | 9.40% 10-K · filed 2026-03-04 | |
| 2023-12-31 | 9.30% 10-K · filed 2025-03-05 | |
| 2022-12-31 | 6.40% 10-K · filed 2024-04-16 | |
| 2022-09-30 | 6.40% 10-Q · filed 2022-11-08 | |
| 2022-06-30 | 6.40% 10-Q · filed 2022-08-05 | |
| 2022-03-31 | 4.40% 10-Q · filed 2022-05-06 | |
| 2021-12-31 | 4.10% 10-K · filed 2023-02-28 | |
| 2021-09-30 | 4.60% 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 4.60% 10-Q · filed 2022-08-05 | |
| 2021-03-31 | 4.60% 10-Q · filed 2022-05-06 | |
| 2020-12-31 | 4.60% 10-K · filed 2022-02-28 | |
| 2020-09-30 | 7.60% 10-Q · filed 2021-11-09 | |
| 2020-06-30 | 7.60% 10-Q · filed 2021-08-06 | |
| 2020-03-31 | 7.60% 10-Q · filed 2021-05-07 | |
| 2019-12-31 | 7.60% 10-K · filed 2022-02-28 | |
| 2019-09-30 | 7.60% 10-Q · filed 2020-11-06 | |
| 2019-06-30 | 7.60% 10-Q · filed 2020-08-14 | |
| 2019-03-31 | 7.60% 10-Q · filed 2020-05-08 | 10.00% 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |